| 1.5 0 (0%) | 10-13 20:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.73 | 1-year : | 4.35 |
| Resists | First : | 2.34 | Second : | 3.72 |
| Pivot price | 2.54  |
|||
| Supports | First : | 0.1 | Second : | 0.09 |
| MAs | MA(5) : | 1.84 |
MA(20) : | 2.75 |
| MA(100) : | 2.94 |
MA(250) : | 1.82  |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 46.8 |
| RSI | RSI(14): 19.3 | |||
| 52-week | High : | 3.86 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EGRX ] has closed above bottom band by 8.2%. Bollinger Bands are 197.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.5 - 1.51 | 1.51 - 1.52 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.48 - 1.5 | 1.5 - 1.51 |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Mon, 06 Oct 2025
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements - The Manila Times
Mon, 06 Oct 2025
Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan
Wed, 17 Sep 2025
Annual Meeting Alert: Eagle Pharmaceuticals Releases Two Years of Audited Financials Ahead of October Meeting - Stock Titan
Mon, 01 Sep 2025
Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors - citybiz
Mon, 18 Aug 2025
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 55.2 (%) |
| Shares Short | 351 (K) |
| Shares Short P.Month | 484 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.25 |
| Profit Margin | 4.6 % |
| Operating Margin | 15.9 % |
| Return on Assets (ttm) | 6.6 % |
| Return on Equity (ttm) | 4.8 % |
| Qtrly Rev. Growth | -12.9 % |
| Gross Profit (p.s.) | 13.87 |
| Sales Per Share | 19.87 |
| EBITDA (p.s.) | 4.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 38 (M) |
| PE Ratio | 3.48 |
| PEG Ratio | 0 |
| Price to Book value | 0.07 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|